GLP-1 Telehealth Safety: Secret Shopper Study Results
You want to lose weight, and GLP-1 telehealth sounds like a fast fix. But a new secret shopper study shows that many online programs skip key safety steps. Let’s look at what the study found, what red flags to watch for, and how to choose a GLP-1 telehealth provider that puts your health first.
Quick Answer: Is GLP-1 Telehealth Safe?
It depends. Some GLP-1 telehealth programs offer full care with live doctor visits and follow-up. But many just use a short form and send pills fast. A Yale study found that only 1 in 4 sites required a video visit. So you need to ask the right questions before you sign up. Safety comes from proper screening, not speed.
What the Secret Shopper Study Found About GLP-1 Telehealth
In July 2026, Yale researchers published a study in the Journal of the American Medical Association that tested 49 online GLP-1 prescribers. They made a fake patient who met the rules for these drugs. Then they tried to get a prescription from each site. The results are shocking: 45 out of 49 sites prescribed the drug. Thirty-four mailed it.
But here’s the problem: only 13 sites (about 26%) asked for a live video call. Just three wanted a phone call. The rest used simple online forms. Many approved the prescription in five minutes or less. Worse, three out of four sites charged and shipped the drug without asking the patient first.
The study also found that only 18% of sites asked if the patient had a primary care doctor. Only 37% wanted any lab results or vitals like blood pressure. Nine sites gave a prescription even when the patient sent just an upper-body photo instead of the full-body photo they said they needed. So if you use a GLP-1 telehealth service, you might get a drug without your doctor knowing.
Compounded GLP-1 Drugs: What the FDA Says
More than half of the products in the study came with extra ingredients, like vitamin B12. That means many telehealth platforms send compounded versions of GLP-1 drugs. Compounded drugs are mixed at special pharmacies. They are not the same as brand-name drugs like Wegovy or Zepbound.
The FDA has warned that compounded GLP-1s are not tested for safety or quality. By May 2026, the FDA had received 990 reports of adverse events associated with compounded semaglutide. Some people ended up in the hospital from dosing mistakes. The FDA also sent warning letters to Hims & Hers and other companies in fall 2025. In February 2026, the FDA said it would take action against companies that claim compounded drugs are the same as approved ones.
On the plus side, compounded GLP-1s cost less. The study found a median price of $217 per month. That’s much cheaper than the $1,000+ for brand-name drugs. But cheap does not mean safe. If you choose a GLP-1 telehealth service that offers compounded drugs, check that the pharmacy has a state license. And know that the product is not FDA approved.
5 Red Flags in GLP-1 Telehealth
Based on the Yale study and FDA alerts, here are warning signs to watch for:
1. No live doctor visit
If the site only has a form and no video or phone call, that’s a big red flag. The study found that less than a third required a live visit. A real doctor should talk with you about your health.
2. No questions about your primary care doctor
Only 18% of sites asked if the patient had a PCP. Your regular doctor needs to know you are on a GLP-1 drug. A good telehealth service connects with your PCP or offers to take over your care.
3. No request for labs or vitals
Only about a third of sites asked for blood pressure or blood sugar levels. Before you start a GLP-1, you should get blood tests for kidney function, liver enzymes, and maybe A1C. If the site does not ask for labs, they are not being careful.
4. Auto-shipment without your okay
Three out of four sites in the study charged and shipped the drug without asking. That is not okay. A good service asks you to confirm before sending any medication.
5. Claims that compounded is the same as brand-name
If a telehealth site says their drug is “just like Wegovy” or “FDA-approved,” walk away. Compounded drugs are not FDA approved. The FDA has said it will take action against false claims.
What Good GLP-1 Telehealth Looks Like
Some GLP-1 telehealth services do it right. A 2025 study in JMIR looked at a remote program that included diet coaching, monthly check-ins, and app support. Patients lost 17 to 22 percent of their body weight in a year. That is close to what you see in a clinic.
So what makes a good program? Look for these things:
- Live video evaluation with a licensed doctor trained in weight loss.
- Baseline blood work and a review of your health history.
- Ongoing care with regular check-ups, dose changes, and side effect help.
- Lifestyle support like diet and exercise guidance. The drug works best with healthy habits.
- A plan for long-term use. Most people regain weight if they stop. As Yale Medicine’s guide to starting GLP-1 medications explains, over 80% of people regain at least a quarter of lost weight within a year of stopping.
5 Questions to Ask Before GLP-1 Telehealth
Before you sign up, ask these questions. If you do not get clear answers, think twice.
- Will I have a live video or phone visit with a real doctor before I get a prescription?
- What blood tests or health history do you need before starting?
- Is the drug brand-name or compounded? If compounded, ask which pharmacy and check if it is licensed.
- What follow-up care do you provide? Dose changes? Side effect support?
- Do you work with my primary care doctor? If not, how do you make sure I have proper care?
The Bottom Line on GLP-1 Telehealth
The Yale study is a warning. GLP-1 telehealth can be helpful and safe when done right. But many sites focus on speed, not health. You can protect yourself by asking the right questions.
Use the checklist above. Talk to your doctor. And if something feels off, trust your gut. Your health is worth taking a few extra minutes to check.
For more on how to start GLP-1s safely, check out Yale Medicine’s guide to starting GLP-1 medications. It shows what good care looks like.
